A61P 39 - General protective or antinoxious agents

Patents for A61P 39 - General protective or antinoxious agents (19,019)
11/2002
11/20/2002	EP1258243A1 Lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy
11/20/2002	EP1257585A2 Antibodies that bind human interleukin-18 and methods of making and using
11/20/2002	EP1257262A2 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof
11/20/2002	EP1257261A2 Antiviral pharmaceutical compositions containing iron chelators
11/20/2002	EP1257253A2 Cosmetic preparations containing plant extracts
11/20/2002	CN1380298A Method for separating and extracting total flavone from goldenrain tree plant and its application
11/20/2002	CN1380068A Medicine for curing enterogastric diseases and its preparation method
11/19/2002	US6482855 Oxidation resistance; stress relieving
11/19/2002	US6482797 N-terminal site selective inhibitors of human angiotensin conversion enzyme (ACE)
11/14/2002	WO2002090559A1 A method for preparing lactic acid fermented solution of mushroom and lactic acid fermented solution of mushroom produced thereby
11/14/2002	WO2002090304A1 Stable solution of reduced coenzyme q
11/14/2002	WO2002089807A1 Timing and duration of administration of adenosine a1/a2 agonist for cardioprotection
11/14/2002	WO2001087317A1 Adsorbent for endocrine disruptors and foods and drinks containing the same
11/14/2002	US20020169150 Hormone replacement therapy
11/14/2002	US20020169131 TGF-alpha polypeptides, functional fragments and methods of use therefor
11/14/2002	US20020169128 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
11/14/2002	DE10119680A1 Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation Use of scavenger compounds for the treatment and prevention of no-dependent disorders of microcirculation
11/14/2002	CA2445713A1 A method for preparing lactic acid fermented solution of mushroom and lactic acid fermented solution of mushroom produced thereby
11/14/2002	CA2408968A1 Adsorbent for endocrine disruptors and foods and drinks containing the same
11/13/2002	EP1256360A1 Hypertonic medicament especially for use in fluid therapy
11/13/2002	EP1256351A1 Novel immune enhancing compositions
11/13/2002	EP1102762B1 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists
11/13/2002	CN1379785A Caspase inhibitors for treatment and prevention of chemotherapy and radiation therapy induced cell death
11/13/2002	CN1379672A Highly selective norepinephrine reuptake inhibitors and methods of using same
11/13/2002	CN1094056C Medicinal tablet with anti-senility function
11/13/2002	CN1094042C Tea water cooling and refreshing function
11/12/2002	US6479540 Compositions of tocol-soluble therapeutics
11/12/2002	US6479500 Alleviating side effects caused by use of an anti-tumor agent comprising administering 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1h,3h)-pyrimidin edione
11/12/2002	US6479477 Substituted porphyrins
11/12/2002	US6479470 Naag and naaladase have been implicated in several pathological conditions relating to glutamate abnormalities and neurotoxicity
11/12/2002	CA2244253C Method for preventing and treating peripheral neuropathy by administering selegiline
11/07/2002	WO2002088316A2 G-protein coupled receptors
11/07/2002	WO2002088159A1 Pharmaceutically active uridine esters
11/07/2002	WO2002088095A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002	WO2002087604A2 Preparations containing a combination of vitamin e and afamin
11/07/2002	WO2002087593A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method
11/07/2002	WO2002087508A2 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002	WO2002069892A3 METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES
11/07/2002	WO2001026676A9 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1)
11/07/2002	US20020165412 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
11/07/2002	US20020165275 Trisubstituted carbocyclic cyclophilin binding compounds and their use
11/07/2002	US20020165165 Free radical scavengers; also use as an amphiphilic lipid to form lipid vesicles; N-octyloxycarbonyl-beta-alanyl-L-histidine, for example
11/07/2002	CA2594883A1 Pharmaceutically active uridine esters
11/07/2002	CA2446514A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002	CA2446064A1 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002	CA2445861A1 Pharmaceutically active uridine esters
11/07/2002	CA2445338A1 G-protein coupled receptors
11/06/2002	EP1254132A1 Food product and process
11/06/2002	EP1254119A1 Pyrimidine derivatives as selective inhibitors of cox-2
11/06/2002	EP1253931A2 Utilization of protein kinase inhibitor alpha
11/06/2002	EP1253904A2 Extracts from residues left in the production of wine
11/06/2002	EP1091966B1 N-terminal site selective inhibitors of human angiotensin conversion enzyme (ace)
11/06/2002	CN1378537A 嘧啶衍生物 Pyrimidine derivatives
11/06/2002	CN1378449A Iron chelators and use thereof
11/05/2002	US6476043 Use of camptothecin derivatives, with reduced gastrointestinal toxicity
11/05/2002	US6475507 Sustained release compositions and the process for their preparation
10/2002
10/31/2002	WO2002085940A2 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002	WO2002085899A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002	WO2002085897A1 Heterocyclic compounds for aging-related and diabetic vascular complications
10/31/2002	WO2002085894A1 Arylindenopyridines with pde inhibiting activity
10/31/2002	WO2002085859A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
10/31/2002	WO2002085382A1 Methods of treating syndrome x with aliphatic polyamines
10/31/2002	WO2002085368A2 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
10/31/2002	WO2002085346A1 Use of creatine for the amelioration of oxidative stress
10/31/2002	WO2002022611A3 Caspase inhibitors and uses thereof
10/31/2002	US20020161019 For treatment of depression, anxiety, feeding disorders, headache, drug addiction, inflammatory disorders
10/31/2002	US20020160499 For use in diagnosis, prophylaxis, and therapy of disorders associated with expression of serine carboxypeptidase
10/31/2002	US20020160481 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof
10/31/2002	US20020159976 An isolated polynucleotide comprising a nucleotide sequence present in Lactobacillus rhamnosus strain HN001 that encodes a polypeptide having atleast one enzymetic activity; genetic engineering
10/31/2002	CA2445188A1 Arylindenopyridines with pde inhibiting activity
10/31/2002	CA2444370A1 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
10/31/2002	CA2444028A1 Methods of treating syndrome x with aliphatic polyamines
10/31/2002	CA2443600A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002	CA2443373A1 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002	CA2442112A1 Use of creatine for the amelioration of oxidative stress
10/30/2002	EP1251829A1 Electrospun pharmaceutical compositions
10/30/2002	CN1377405A Personal care articles
10/30/2002	CN1377366A 5-hydroxysapogenin derivatives with anti-dementia activity
10/30/2002	CN1377352A Selective antagonists of A28 adenosine receptors
10/30/2002	CN1377267A Retard form containing 2-lipoic acid (derivatives)
10/30/2002	CN1377266A Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion
10/30/2002	CN1376496A Antagonistic decomposer for nicotine toxin
10/30/2002	CN1093400C Oral preparation with dimethoate detoxicating
10/29/2002	US6472395 Agent for use in transplantation
10/29/2002	US6472183 Immunity against Actinobacillus pleuropneumoniae's RTX toxins APX
10/24/2002	WO2002083628A1 1,4-disubstituted benzo-fused compounds
10/24/2002	WO2002083624A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
10/24/2002	WO2002003972A3 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
10/24/2002	US20020156264 And method of using the carboxypeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in carboxypeptidase-related disorders
10/24/2002	US20020155597 In vivo production and delivery of erthropoietin or insulinotropin for gene therapy
10/24/2002	CA2443697A1 1,4-disubstituted benzo-fused compounds
10/23/2002	EP1250153A2 TREATMENT OF i C. DIFFICILE /i TOXIN B ASSOCIATED CONDITIONS
10/23/2002	EP1250142A1 Multivalent electron active compositions and methods of making and using same
10/23/2002	EP0914118B1 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
10/23/2002	CN1375330A Toxicopathy treating composite medicine
10/23/2002	CN1375295A Functional water containing antioxidant radical natural medicament component and its production process
10/22/2002	US6469162 Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy and diagnosis
10/22/2002	US6468542 Germination activated Ganoderma lucidum spores and method for producing the same
10/17/2002	WO2002081728A2 Quinoline inhibitors of hyak1 and hyak3 kinases
10/17/2002	WO2002081487A1 Low concentration rates

1 ... 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 ... 191